Neuroprotective effects of stemazole in the MPTP-induced acute model of Parkinson's disease: Involvement of the dopamine system

Neuroscience Letters

Volumn 616, Issue , 2016, Pages 152-159

  Guo, Zhirui ^a   Xu, Shasha ^a   Du, Na ^a   Liu, Jia ^a   Huang, Yiyun ^b   Han, Mei ^a  

^a BEIJING NORMAL UNIVERSITY   (China)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Dopamine system; MPTP; Neuroprotection; Oxidative stress; Parkinson's disease; Stemazole

Indexed keywords

BENSERAZIDE PLUS LEVODOPA; DOPAMINE TRANSPORTER; GLUTATHIONE PEROXIDASE; NEUROPROTECTIVE AGENT; STEMAZOLE; SUPEROXIDE DISMUTASE; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; BENSERAZIDE; BENSERAZIDE, LEVODOPA DRUG COMBINATION; DOPAMINE; DRUG COMBINATION; HYDRAZINE DERIVATIVE; HYDRAZINECARBOTHIOAMIDE,N-(4-(4,5-DIHYDRO-5-THIOXO-1,3,4-OXADIAZOL-2-YL)PHENYL); LEVODOPA; OXADIAZOLE DERIVATIVE;

ACUTE DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COUNT; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE METABOLISM; DOPAMINERGIC SYSTEM; DRUG EFFECT; DRUG MEGADOSE; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME ANALYSIS; LATENT PERIOD; LOCOMOTION; LOW DRUG DOSE; MALE; MOTOR COORDINATION; MOTOR DYSFUNCTION; MOUSE; MPTP-INDUCED PARKINSONISM; NERVE CELL; NEUROPROTECTION; NONHUMAN; OPTICAL DENSITY; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN ANALYSIS; TISSUE LEVEL; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TURNOVER TIME; UPREGULATION; ANIMAL; C57BL MOUSE; DRUG COMBINATION; DRUG EFFECTS; METABOLISM; MOTOR ACTIVITY; PARKINSON DISEASE; PSYCHOLOGY; SUBSTANTIA NIGRA;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; BENSERAZIDE; CORPUS STRIATUM; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DRUG COMBINATIONS; HYDRAZINES; LEVODOPA; MALE; MICE, INBRED C57BL; MOTOR ACTIVITY; NEUROPROTECTIVE AGENTS; OXADIAZOLES; OXIDATIVE STRESS; PARKINSON DISEASE; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

EID: 84957090699     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2016.01.048     Document Type: Article

References (32)

1. Oida Y., et al. Rifampicin attenuates the MPTP-induced neurotoxicity in mouse brain. Brain Res. 2006, 1082:196-204.
2. Elsworth J.D., Roth R.H. Dopamine synthesis, uptake, metabolism, and receptors: relevance to gene therapy of Parkinson's disease. Exp. Neurol. 1997, 144(1):4-9.
3. Davie C.A. A review of Parkinson's disease. Br. Med. Bull. 2008, 86:109-127.
4. Sun Y., et al. Synthesis and biological evaluation of a novel human stem/progenitor cells proliferation activator: 4-(4-(5-mercapto-1,3,4-oxadiazol-2-yl)phenyl) thiosemicarbazide (Stemazole). Eur. J. Med. Chem. 2011, 46(7):2930-2936.
5. Han M., et al. Therapeutic efficacy of stemazole in a beta-amyloid injection rat model of Alzheimer's disease. Eur. J. Pharmacol. 2011, 657(1-3):104-110.
6. Przedborski S., Vila M. MPTP: a review of its mechanisms of neurotoxicity. Clin. Neurosci. Res. 2001, 1(6):407-418.
7. Mc Guire P.J., Parikh A., Diaz G.A. Profiling of oxidative stress in patients with inborn errors of metabolism. Mol. Genet. Metab. 2009, 98(1-2):173-180.
8. Jenner P., Olanow C.W. Oxidative stress and the pathogenesis of Parkinson's disease. Neurology 1996, 47(6):S161-S170.
9. Zhang J., et al. Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons. Am. J. Pathol. 1999, 154(5):1423-1429.
10. Li X.M., et al. Ameliorative and neuroprotective effect in MPTP model of Parkinson's disease by Zhen-Wu-Tang (ZWT): a traditional Chinese medicine. J. Ethnopharmacol. 2010, 130(1):19-27.
11. Jackson-Lewis V., Przedborski S. Protocol for the MPTP mouse model of Parkinson's disease. Nat. Protoc. 2007, 2(1):141-151.
12. Liu J., et al. Neuroprotective effects of Jitai Tablet, a traditional Chinese medicine, on the MPTP-induced acute model of Parkinson's disease: involvement of the dopamine system. Evid.-based Complement. Altern. Med. 2014, 2014:542383.
13. Zhang H.N., An C.N., Pu X.P. Protocatechuic acid inhibits neurotoxicity induced by MPTP in vivo. Neurosci. Lett. 2010, 474(2):99-103.
14. Chung Y.C., et al. Fluoxetine prevents MPTP-induced loss of dopaminergic neurons by inhibiting microglial activation. Neuropharmacology 2011, 60(6):963-974.
15. Luo D.Z., et al. Fucoidan protects against dopaminergic neuron death in vivo and in vitro. Eur. J. Pharmacol. 2009, 617(1-3):33-40.
16. Lowry O.H., et al. Protein measurement with the folin phenol reagent. J. Biol. Chem. 1951, 193(1):265-275.
17. Taylor T.N., Greene J.G., Miller G.W. Behavioral phenotyping of mouse models of Parkinson's disease. Behav. Brain Res. 2010, 211(1):1-10.
18. Jacksonlewis V., et al. Time-course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurodegeneration 1995, 4(3):257-269.
19. Ishikawa S., et al. Human DJ-1-specific transcriptional activation of tyrosine hydroxylase gene. J. Biol. Chem. 2010, 285(51):39718-39731.
20. Hosp J.A., et al. Dopaminergic projections from midbrain to primary motor cortex mediate motor skill learning. J. Neurosci. 2011, 31(7):2481-2487.
21. Winogrodzka A., et al. I-123 beta-CIT SPECT is a useful method for monitoring dopaminergic degeneration in early stage Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 2003, 74(3):294-298.
22. Ravina B., et al. Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease. Mov. Disord. 2012, 27(11):1392-1397.
23. Sowell R.A., Owen J.B., Butterfield D.A. Proteomics in animal models of Alzheimer's and Parkinson's diseases. Ageing Res. Rev. 2009, 8(1):1-17.
24. Carder R.K., et al. Dopamine released from mesencephalic transplants restores modulation of striatal acetylcholine-release after neonatal 6-hydroxydopamine-an invitro analysis. Exp. Neurol. 1989, 105(3):251-259.
25. Bloem B.R., et al. The MPTP model-versatile contributions to the treatment of idiopathic Parkinsons-disease. J. Neurol. Sci. 1990, 97(2-3):273-293.
26. Geng X.C., et al. Neuroprotective effects of echinacoside in the mouse MPTP model of Parkinson's disease. Eur. J. Pharmacol. 2007, 564(1-3):66-74.
27. Heikkila R.E., Hess A., Duvoisin R.C. Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice. Science 1984, 224(4656):1451-1453.
28. Henderson J.M., et al. Relationships between various behavioural abnormalities and nigrostriatal dopamine depletion in the unilateral 6-OHDA-lesioned rat. Behav. Brain Res. 2003, 139(1-2):105-113.
29. Haobam R., et al. Swim-test as a function of motor impairment in MPTP model of Parkinson's disease: a comparative study in two mouse strains. Behav. Brain Res. 2005, 163(2):159-167.
30. Ahlskog J.E. Beating a dead horse-dopamine and Parkinson disease. Neurology 2007, 69(17):1701-1711.
31. Cui H., Kong Y., Zhang H. Oxidative stress, mitochondrial dysfunction, and aging. J. Signal Transduct. 2012, 2012:646354.
32. Weydert C.J., Cullen J.J. Measurement of superoxide dismutase, catalase and glutathione peroxidase in cultured cells and tissue. Nat. Protoc. 2010, 5(1):51-66.